Here, we explored whether the add-on of PARP inhibitors and ATO has a synergistically apoptotic effect in HR-proficient ovarian cancer cells, since both the PARP inhibitors and ATO act to regulate DNA damage signaling. Here, PARP1 is linked to ovarian carcinoma.